Avecho Biotechnology Limited

ASX:AVE Stok Raporu

Piyasa değeri: AU$9.5m

Avecho Biotechnology Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Avecho Biotechnology's earnings have been declining at an average annual rate of -26.6%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been declining at an average rate of 43.3% per year.

Anahtar bilgiler

-26.6%

Kazanç büyüme oranı

-19.4%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi31.2%
Gelir büyüme oranı-43.3%
Özkaynak getirisi-82.6%
Net Marj-1,026.9%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth

Jan 13
Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth

Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation

May 31
Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation

Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth Plans

Nov 04
Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely

Jul 14
We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely

We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth

Mar 23
We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth

We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn Rate

Dec 08
We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn Rate

Gelir ve Gider Dağılımı

Avecho Biotechnology nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

ASX:AVE Gelir, gider ve kazançlar (AUD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 240-321
31 Mar 240-321
31 Dec 230-321
30 Sep 231-431
30 Jun 231-431
31 Mar 231-331
31 Dec 221-221
30 Sep 221-221
30 Jun 221-231
31 Mar 221-331
31 Dec 211-331
30 Sep 211-331
30 Jun 210-331
31 Mar 210-330
31 Dec 200-330
30 Sep 200-220
30 Jun 200-220
31 Mar 202-120
31 Dec 194120
30 Sep 194120
30 Jun 195030
31 Mar 193-230
31 Dec 181-440
30 Jun 181-661
31 Mar 181-771
31 Dec 171-981
30 Jun 171-1681
31 Mar 171-1781
31 Dec 162-1782
30 Sep 162-1792
30 Jun 163-1792
31 Mar 162-1892
31 Dec 152-2092
30 Sep 152-1782
30 Jun 153-1473
31 Mar 152-1063
31 Dec 142-763
30 Jun 141-763
31 Mar 141-973
31 Dec 131-1174

Kaliteli Kazançlar: AVE is currently unprofitable.

Büyüyen Kar Marjı: AVE is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: AVE is unprofitable, and losses have increased over the past 5 years at a rate of 26.6% per year.

Büyüme Hızlandırma: Unable to compare AVE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: AVE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).


Özkaynak Getirisi

Yüksek ROE: AVE has a negative Return on Equity (-82.63%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin